727 related articles for article (PubMed ID: 27147513)
1. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.
Sepúlveda M; Armangue T; Martinez-Hernandez E; Arrambide G; Sola-Valls N; Sabater L; Téllez N; Midaglia L; Ariño H; Peschl P; Reindl M; Rovira A; Montalban X; Blanco Y; Dalmau J; Graus F; Saiz A
J Neurol; 2016 Jul; 263(7):1349-60. PubMed ID: 27147513
[TBL] [Abstract][Full Text] [Related]
2. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
5. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
7. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
8. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
[TBL] [Abstract][Full Text] [Related]
9. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
Ungureanu A; de Seze J; Ahle G; Sellal F
Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.
Konuskan B; Yildirim M; Gocmen R; Okur TD; Polat I; Kilic H; Saltik S; Ozturk Z; Gucuyener K; Altunbasak S; Celik T; Kose G; Yilmaz A; Komur M; Kayilioglu H; Anlar B
Mult Scler Relat Disord; 2018 Nov; 26():1-7. PubMed ID: 30212767
[TBL] [Abstract][Full Text] [Related]
11. MOG antibody-related disorders: common features and uncommon presentations.
Cobo-Calvo Á; Ruiz A; D'Indy H; Poulat AL; Carneiro M; Philippe N; Durand-Dubief F; Deiva K; Vukusic S; Desportes V; Marignier R
J Neurol; 2017 Sep; 264(9):1945-1955. PubMed ID: 28770374
[TBL] [Abstract][Full Text] [Related]
12. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder.
Salama S; Pardo S; Levy M
Mult Scler Relat Disord; 2019 May; 30():231-235. PubMed ID: 30825703
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
Höftberger R; Sepulveda M; Armangue T; Blanco Y; Rostásy K; Calvo AC; Olascoaga J; Ramió-Torrentà L; Reindl M; Benito-León J; Casanova B; Arrambide G; Sabater L; Graus F; Dalmau J; Saiz A
Mult Scler; 2015 Jun; 21(7):866-874. PubMed ID: 25344373
[TBL] [Abstract][Full Text] [Related]
15. Clinical and MRI phenotype of children with MOG antibodies.
Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
[TBL] [Abstract][Full Text] [Related]
18. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
[TBL] [Abstract][Full Text] [Related]
19. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
[TBL] [Abstract][Full Text] [Related]
20. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]